TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35502609

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin with bendamustine and rituximab (Pola-BR)
Number of subjects: 21
Study: 35502771

Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Instantaneous Wave-Free Ratio (iFR)
Number of subjects: 1564
Study: 35502871

Group type: EXPERIMENTAL
Intervention: Gastric emptying scintigraphy (GES) meal
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Water load satiety test (WLST)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Delayed gastric emptying
Number of subjects: 109
Study: 35503163

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg qw
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg q2w
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg qw or q2w
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2677
Study: 35503244

Group type: EXPERIMENTAL
Intervention: Sunnyside (6-week cognitive behavioral therapy-based web-based intervention)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sunnyside Plus (6-week cognitive behavioral therapy-based web-based intervention with additional education and support for human milk feeding)
Number of subjects: 22
Study: 35503708

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 47
Study: 35503774

Group type: EXPERIMENTAL
Intervention: Below-the-ankle (BTA) intervention
Number of subjects: 0
Study: 35504121

Group type: EXPERIMENTAL
Intervention: Plantar pressure in the lateral forefoot
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Early stance center of pressure
Number of subjects: 25
Study: 35504168

Group type: EXPERIMENTAL
Intervention: Phase angle measurement on ICU admission
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Presence of malignancy
Number of subjects: 1023
Study: 35504244

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every two weeks for 26 cycles
Number of subjects: 27
Study: 35504641

Group type: EXPERIMENTAL
Intervention: cPRO assessments (pain, fatigue, physical function, depression, anxiety and supportive care needs) before medical oncology visits.
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: cPRO implementation over 12 months.
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Patient-reported healthcare utilisation and quality, symptoms and health-related quality of life measures at baseline, 6 and 12 months.
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Focus groups or interviews with patients (n=50) and surveys with clinicians and administrators (n=40).
Number of subjects: 4000
Study: 35504640

Group type: EXPERIMENTAL
Intervention: Decentralised, one-stop-shop model of care
Number of subjects: 0
Study: 35505001

Group type: EXPERIMENTAL
Intervention: Patients with SB
Number of subjects: 36
Study: 35505238

Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in likely insulin allergy patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in possible insulin allergy patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in unlikely insulin allergy patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in case-control study
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Skin prick and serum anti-insulin IgE tests in case-control study
Number of subjects: 52
Study: 35505290

Group type: EXPERIMENTAL
Intervention: Individually tailored dietary counseling for six months, focusing on increasing protein and energy intake.
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Individually tailored dietary counseling for six months.
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 199
Study: 35505330

Group type: EXPERIMENTAL
Intervention: FFI-RSN (Foot Function Index revised short form)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: FFI-RSN
Number of subjects: 139
Study: 35505358

Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational intervention for hospital staff
Number of subjects: 23
Study: 35505383

Group type: EXPERIMENTAL
Intervention: Computer-assisted motivational interviewing social network intervention (MI-SNI)
Number of subjects: 15
Study: 35505384

Group type: COMPARATOR
Intervention: High-risk group (based on the predictive model)
Number of subjects: 470
Study: 35505404

Group type: EXPERIMENTAL
Intervention: Referral-based transition to continued rehabilitation in the home
Number of subjects: 190
Study: 35505418

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Study group (patients with PE)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Study group (patients with PE) after Nuss surgery
Number of subjects: 34
Study: 35506108

Group type: EXPERIMENTAL
Intervention: GSK2586881 (0.1, 0.2, 0.4, or 0.8 mg/kg, single intravenous dose)
Number of subjects: 0
Study: 35506190

Group type: EXPERIMENTAL
Intervention: Daily mango consumption, dosage not specified, duration not specified
Number of subjects: 0
Study: 35506244

Group type: EXPERIMENTAL
Intervention: Prior history of serrated polyps
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Alcohol and smoking exposure
Number of subjects: 2102
Study: 35506349

Group type: EXPERIMENTAL
Intervention: Natural History cohort (ALGS NH)
Number of subjects: 59
Study: 35506389

Group type: EXPERIMENTAL
Intervention: Antioxidants (various types, doses, and combinations)
Number of subjects: 10303
Study: 35507014

Group type: EXPERIMENTAL
Intervention: Doxorubicin-cyclophosphamide-based neoadjuvant therapy
Number of subjects: 211
Study: 35507146

Group type: EXPERIMENTAL
Intervention: Youth with T1DM
Number of subjects: 70

Group type: COMPARATOR
Intervention: Controls without T1DM
Number of subjects: 70
Study: 35507355

Group type: EXPERIMENTAL
Intervention: Standard 2-dose SARS-CoV-2 vaccination regimen
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Third dose of SARS-CoV-2 vaccine
Number of subjects: 1505
Study: 35507396

Group type: EXPERIMENTAL
Intervention: CDSS intervention in treatment practices
Number of subjects: 2423

Group type: EXPERIMENTAL
Intervention: CDSS intervention in treatment practices (subgroup analysis)
Number of subjects: 2423

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 2423
Study: 35507403

Group type: EXPERIMENTAL
Intervention: Standard of care + circuit-based resistance training exercise group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard of care waitlist control group
Number of subjects: 38
Study: 35507406

Group type: EXPERIMENTAL
Intervention: Safer conception intervention (Sinikithemba Kwabesilisa) with 3 counseling and 2 booster sessions over 12 weeks, promoting ART uptake and adherence, HIV serostatus disclosure, and safer conception strategies.
Number of subjects: 16
Study: 35507536

Group type: EXPERIMENTAL
Intervention: BOXR1030 (GPC3-targeted CAR T cell co-expressing GOT2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control GPC3 CAR alone
Number of subjects: 0
Study: 35507606

Group type: EXPERIMENTAL
Intervention: Darunavir-cobicistat
Number of subjects: 400

Group type: COMPARATOR
Intervention: Lopinavir-ritonavir
Number of subjects: 400
Study: 35507739

Group type: EXPERIMENTAL
Intervention: Maralixibat 266 μg/kg orally, once daily, from baseline to Week 72, with twice-daily dosing permitted from Week 72.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Maralixibat
Number of subjects: 33
Study: 35507774

Group type: EXPERIMENTAL
Intervention: MUSTCOOL cooling intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo cooling patch intervention
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MUSTCOOL cooling intervention for DFU
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo cooling patch intervention for DFU
Number of subjects: 140
Study: 35507946

Group type: EXPERIMENTAL
Intervention: Water-Free Omega-3 Fatty Acid Eye Drop
Number of subjects: 0
Study: 35507993

Group type: EXPERIMENTAL
Intervention: Innovations in logistics and coordination of activities
Number of subjects: 1105
Study: 35508003

Group type: EXPERIMENTAL
Intervention: Continuous passive plantar flexor stretching for 120 seconds
Number of subjects: 24
Study: 35508341

Group type: EXPERIMENTAL
Intervention: Educational intervention on elder abuse (full-day education including theory, group discussions, forum theatre, and post-training reflection)
Number of subjects: 750
Study: 35508346

Group type: EXPERIMENTAL
Intervention: Ustekinumab induction dose
Number of subjects: 140
Study: 35508390

Group type: EXPERIMENTAL
Intervention: ICP monitoring
Number of subjects: 587

Group type: COMPARATOR
Intervention: Non-monitored patients
Number of subjects: 587
Study: 35508515

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection at M3
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Working department specialty
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Age, sex, professional category, years of experience, public transportation use
Number of subjects: 1062
Study: 35508559

Group type: EXPERIMENTAL
Intervention: Sit Down and Play intervention during routine immunization visits
Number of subjects: 53

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 53
Study: 35508986

Group type: EXPERIMENTAL
Intervention: CAB + RPV every 8 weeks (Q8W)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Daily oral standard of care (SoC)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CAB + RPV Q8W
Number of subjects: 918

Group type: COMPARATOR
Intervention: Daily oral SoC
Number of subjects: 918
Study: 35509022

Group type: EXPERIMENTAL
Intervention: Magnetically controlled capsule endoscopy (MCE)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Magnetically controlled capsule endoscopy (MCE) with magnetic steering
Number of subjects: 768
Study: 35509030

Group type: EXPERIMENTAL
Intervention: Withing Steel HR activity tracker for 12 months
Number of subjects: 300
Study: 35509435

Group type: EXPERIMENTAL
Intervention: Shape-sensing robotic-assisted bronchoscopy (SSRAB) combined with portable 3D imaging
Number of subjects: 30
Study: 35510128

Group type: EXPERIMENTAL
Intervention: ODI4% ≥5 episodes/hour
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: ODI4% ≥10 episodes/hour
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: ODI4% ≥15 episodes/hour
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: ODI4%
Number of subjects: 1072
Study: 35510546

Group type: EXPERIMENTAL
Intervention: HF-CS
Number of subjects: 520

Group type: COMPARATOR
Intervention: AMI-CS
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 520
Study: 35510547

Group type: EXPERIMENTAL
Intervention: Economic empowerment added to traditional HIV risk reduction education
Number of subjects: 542

Group type: COMPARATOR
Intervention: Traditional HIV risk reduction education
Number of subjects: 542
Study: 35510711

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment (e.g., low-molecular-weight heparin)
Number of subjects: 206

Group type: COMPARATOR
Intervention: No anticoagulation treatment
Number of subjects: 206
Study: 35510813

Group type: EXPERIMENTAL
Intervention: Higher pre-stroke socioeconomic status (SES)
Number of subjects: 176
Study: 35511120

Group type: EXPERIMENTAL
Intervention: 0.01% atropine with soft multifocal contact lenses (SMCLs)
Number of subjects: 138

Group type: COMPARATOR
Intervention: soft multifocal contact lenses (SMCLs) alone
Number of subjects: 138

Group type: COMPARATOR
Intervention: single-vision contact lenses
Number of subjects: 138
Study: 35511148

Group type: EXPERIMENTAL
Intervention: MRG003 (0.1 to 2.5 mg/kg administered every 3 weeks during phase 1a; recommended dose of 2.5 mg/kg during phase 1b)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MRG003
Number of subjects: 61
Study: 35511170

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Number of subjects: 505

Group type: COMPARATOR
Intervention: Appropriate medical therapy
Number of subjects: 505
Study: 35511225

Group type: EXPERIMENTAL
Intervention: TAKE IT intervention (multifaceted adherence monitoring strategy)
Number of subjects: 449
Study: 35511229

Group type: EXPERIMENTAL
Intervention: ElderTree on a smart display along with usual care
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: ElderTree on a touch screen laptop along with usual care
Number of subjects: 291

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 291
Study: 35511286

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 709
Study: 35511527

Group type: EXPERIMENTAL
Intervention: Short Inventory of Problems (SIP-2R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multigroup confirmatory factor analysis (MGCFA) model comprising one general alcohol-related harm factor
Number of subjects: 0
Study: 35511740

Group type: EXPERIMENTAL
Intervention: IMGC936 (a next-generation maytansinoid-based antibody-drug conjugate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMGC936
Number of subjects: 0
Study: 35511761

Group type: EXPERIMENTAL
Intervention: Aztreonam lysine (AZLI; Cayston®) for 4 weeks
Number of subjects: 18
Study: 35511917

Group type: COMPARATOR
Intervention: Chemotherapy control arms from four NSCLC RCTs (IMpower150-WT, IMpower130-WT, IMpower131, IMpower132)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-world data (RWD) external controls
Number of subjects: 0
Study: 35511920

Group type: EXPERIMENTAL
Intervention: Orally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mucosally vaccinated, SARS-CoV-2-infected hamsters
Number of subjects: 0
Study: 35512229

Group type: EXPERIMENTAL
Intervention: Perceived frailty (subjective assessment by physicians)
Number of subjects: 13621

Group type: EXPERIMENTAL
Intervention: Objective frailty (Modified Frailty Index)
Number of subjects: 13621

Group type: EXPERIMENTAL
Intervention: Non-recommended edoxaban dose regimens
Number of subjects: 13621

Group type: COMPARATOR
Intervention: Comparison of perceived frailty vs. objective frailty
Number of subjects: 13621
Study: 35512369

Group type: EXPERIMENTAL
Intervention: Plant-based diet (PBD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 18
Study: 35512742

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) using a low-energy X-ray source (50 kV, Intrabeam, Carl Zeiss) with 10 Gy prescribed at a 5-mm depth from the tumor bed.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with adjuvant gemcitabine-based chemotherapy administered 8-12 weeks after surgery.
Number of subjects: 41
Study: 35512743

Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment with VerifyNow assay results
Number of subjects: 13160

Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype analysis
Number of subjects: 13160
Study: 35512761

Group type: EXPERIMENTAL
Intervention: Almonds
Number of subjects: 73
Study: 35513751

Group type: EXPERIMENTAL
Intervention: One occurrence of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Two or more occurrences of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Number of subjects: 1000
Study: 35513779

Group type: EXPERIMENTAL
Intervention: Progesterone therapy
Number of subjects: 6615

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 6615
Study: 35513807

Group type: EXPERIMENTAL
Intervention: Hybrid learning environment
Number of subjects: 376

Group type: COMPARATOR
Intervention: Distance learning environment
Number of subjects: 376
Study: 35513826

Group type: EXPERIMENTAL
Intervention: Conventional dose of LMWH (> 100 IU/kg/day)
Number of subjects: 5870

Group type: EXPERIMENTAL
Intervention: Adjusted dose of LMWH (≤ 100 IU/kg/day)
Number of subjects: 5870

Group type: EXPERIMENTAL
Intervention: Adjusted dose of LMWH
Number of subjects: 5870

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 5870
Study: 35513832

Group type: EXPERIMENTAL
Intervention: Anlotinib combined with capecitabine and oxaliplatin
Number of subjects: 30
Study: 35513845

Group type: EXPERIMENTAL
Intervention: Postoperative immune-inflammatory scores (PLR, lymphocyte count, PNI)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Preoperative immune-inflammatory scores (NLR, PLR, LMR, PNI, SII)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Postoperative lymphocyte count
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Postoperative PLR
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Postoperative PNI
Number of subjects: 312
Study: 35514021

Group type: EXPERIMENTAL
Intervention: Early detection of overweight through primary health care contacts (including dental care)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Follow-up examination after approximately one year
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk markers in school children with overweight
Number of subjects: 992
Study: 35514111

Group type: EXPERIMENTAL
Intervention: Test-based attendance strategy (daily rapid antigen testing, stay at work if negative)
Number of subjects: 24027

Group type: COMPARATOR
Intervention: Standard 10-day self-isolation
Number of subjects: 24027
Study: 35514131

Group type: COMPARATOR
Intervention: Educational interventions for health professionals
Number of subjects: 4936
Study: 35514201

Group type: EXPERIMENTAL
Intervention: Eculizumab (1200 mg IV on Day 1, additional doses of 1200 mg IV on Days 4 and 8; 900 mg IV on Days 15 and 22; optional doses on Days 12 and 18)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 8
Study: 35514770

Group type: EXPERIMENTAL
Intervention: Treprostinil inhalation powder (TreT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treprostinil inhalation solution
Number of subjects: 51
Study: 35516461

Group type: EXPERIMENTAL
Intervention: salvage radiotherapy (sRT) delivering 66-69 Gy and 73.5 Gy in 30 fractions to the whole prostatic fossa and to the local failure(s) seen at DCE-MRI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: salvage radiotherapy (sRT)
Number of subjects: 62
Study: 35517914

Group type: EXPERIMENTAL
Intervention: NKTR-358 (0.3-28.0 μg/kg in SAD; 3-24.0 μg/kg in MAD)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: NKTR-358
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 35518121

Group type: EXPERIMENTAL
Intervention: Vibrating capsule (VC), two capsules per week for six weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 107
Study: 35518929

Group type: EXPERIMENTAL
Intervention: Elevated aldosterone-renin ratio
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Saline loading test
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Clinical characteristics and elevated aldosterone-renin ratio
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall prevalence of primary aldosteronism
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prevalence of primary aldosteronism in cardioembolic stroke
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prevalence of primary aldosteronism in resistant hypertension
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Prevalence of primary aldosteronism in hypertension and atrial fibrillation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Screening for primary aldosteronism
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Decision tree for screening
Number of subjects: 300
Study: 35521657

Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736) with Tremelimumab in combination with image-guided stereotactic body radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35521767

Group type: EXPERIMENTAL
Intervention: Serum LH/FSH ratios
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Urinary LH/FSH ratios
Number of subjects: 236
Study: 35522297

Group type: EXPERIMENTAL
Intervention: OCTA (Optical Coherence Tomography Angiography)
Number of subjects: 89

Group type: COMPARATOR
Intervention: ICGA (Indocyanine Green Angiography)
Number of subjects: 89
Study: 35522459

Group type: EXPERIMENTAL
Intervention: Guided internet intervention for prolonged grief symptoms
Number of subjects: 100
Study: 35522464

Group type: EXPERIMENTAL
Intervention: Teleprehabilitation (multimodal virtual prehabilitation services)
Number of subjects: 100
Study: 35522466

Group type: EXPERIMENTAL
Intervention: Facebook weight loss group with open enrollment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Facebook weight loss group with closed enrollment
Number of subjects: 68
Study: 35522941

Group type: EXPERIMENTAL
Intervention: PD-L1/TIGIT bispecific antibody
Number of subjects: 0
Study: 35522969

Group type: EXPERIMENTAL
Intervention: Adapted 2019 International Society for Heart and Lung Transplantation (ISHLT) criteria for chronic lung allograft dysfunction (CLAD)
Number of subjects: 166

Group type: COMPARATOR
Intervention: NIH criteria for bronchiolitis obliterans syndrome (BOS)
Number of subjects: 166
Study: 35523118

Group type: EXPERIMENTAL
Intervention: Desmopressin administered IV
Number of subjects: 75
Study: 35523519

Group type: EXPERIMENTAL
Intervention: Lowest GDP/capita countries
Number of subjects: 439

Group type: COMPARATOR
Intervention: Middle GDP/capita countries
Number of subjects: 439

Group type: COMPARATOR
Intervention: High GDP/capita countries
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 439
Study: 35523659

Group type: EXPERIMENTAL
Intervention: Complicated CAP ipsilateral to acute ischemic anterior circulation stroke (icCAP)
Number of subjects: 196

Group type: COMPARATOR
Intervention: No icCAP
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Complicated CAP ipsilateral to acute ischemic anterior circulation stroke (icCAP) in patients with cryptogenic stroke
Number of subjects: 196

Group type: COMPARATOR
Intervention: No icCAP in patients with cryptogenic stroke
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Ruptured fibrous cap
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage
Number of subjects: 196
Study: 35523696

Group type: EXPERIMENTAL
Intervention: Up-to-date care for T2DM
Number of subjects: 73484
Study: 35523821

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 10 weeks
Number of subjects: 12
Study: 35524015

Group type: EXPERIMENTAL
Intervention: Patient-specific PEEK implant
Number of subjects: 8